Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-labelled, Multicenter Phase II Study of Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)

NCT01054781 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT01054781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01054781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-labelled, Multicenter Phase II Study of Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
Not reported
Enrollment
91 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma (dlbcl)